Research Clinical Implementation of Pharmacogenomics
For customers interested in evaluating the efficacy and impact of pharmacogenomics in clinical situations, under a research protocol, we offer services to interrogate the “pharmacogenome”. Personalis uses its ACE technology, in combination with its proprietary and comprehensive pharmacogenomics database, to query the set of genes for which there is published evidence of impact on drug response. These include high-evidence associations between genetic variations and drug response, including warfarin, clopidogrel, simvastatin, thiopurines, codeine, abacavir and allopurinol, as well as medium- and low-evidence associations for hundreds of other drugs that may be of interest for advancing understanding of their role or impact on clinical care. Personalis pharmacogenomics capabilities allow the accurate measurement of not only common variations, but also the assessment of rare variation in key regions of the exome, and key splice-site and regulatory regions. Personalis can produce focused panels of genes of interest, including specialty-specific panels as well as easy-to-read reports describing the likely genetic influence on drug response.